Project Grant R01DK140405
- Federal Project Grant Award Summary Cincinnati Children's Hospital Medical Center received a $851,275 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective February 15, 2026, with a completion date of December 31, 2029. The research project, titled "Mechanisms Regulating Competency of Hepatocyte Plasticity," investigates...
- The National Institute on Aging (NIA) awarded a $442,750 Project Grant (CFDA 93.866) to Duke University to conduct research on using heterochronic (age-mismatched) hepatocyte transplantation to rejuvenate the aged liver. The research aims to understand how transplanting young hepatocytes into old livers, and vice versa, can influence liver function, cellular composition, and the plasma proteome. Key objectives include measuring changes in liver function markers, analyzing the liver's cellular...
- The University of Pennsylvania received a $665,725 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective February 1, 2026, with a completion date of December 31, 2029. This research initiative delivers fundamental biomedical research and molecular genetic analysis focused on understanding the role of cellular senescence in liver disease...
- This Project Grant award of $154,860 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research investigating the mechanisms of clonal competition in age-related clonal hematopoiesis. The research, conducted by Boston Children's Hospital and awarded effective August 1, 2025, through May 31, 2028, focuses on understanding how hematopoietic stem cell mutations...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $426,425 to Baylor College of Medicine to conduct a pilot study examining the relationship between gut microbiome composition, metabolic dysfunction-associated steatotic liver disease (MASLD), and hepatocellular carcinoma (HCC). The key objectives of this 2-year study are to: 1) characterize baseline gut microbiome diversity associated with MASLD with and without HCC, 2)...
- Federal Grant Award Summary BLIPS: Biocompatible Liver in Pigs Renovate Biosciences Inc. received a $584,232 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on September 25, 2025. The grant supports research and development of xenotransplantation technology to generate human livers from patient-specific donor cells using pigs as bio-incubators. This...
- Federal Project Grant Award Summary Hepatx Corporation received a $175,964 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded on May 13, 2025, with completion targeted for April 30, 2027. The company will develop and validate a proteomic blood test to monitor the success of transplanted hepatocytes in human patients. Using mass spectrometry methods to...
- Grant Summary: ASK1 Inhibitor Development for Biliary Atresia Treatment Seal Rock Therapeutics, Inc. received a $693,820 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on September 15, 2025, with completion targeted for August 31, 2026. The award funds preclinical research and development activities for SRT-015, a novel Apoptosis Signal-regulating...
- Federal Project Grant Award Summary Oregon Health & Science University received a $1,992,234 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective July 1, 2025, through April 30, 2030. This award funds research on allogeneic hepatocyte transplantation designed to overcome critical barriers to therapeutic liver cell therapy by developing genetically...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded The Children's Hospital of Philadelphia (CHOP) a Project Grant of $159,408 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). This five-year mentored clinical scientist research career development award, with a completion date of July 31, 2030, supports investigator-initiated research aimed at improving understanding...
COMBATING CHRONIC LIVER DISEASES VIA UNDERSTANDING AND ENGINEERING CELL COMPETITION AND FITNESS - SUMMARY: CELL COMPETITION REMOVES MUTATED CELLS AND ENABLES ROBUST TISSUE DEVELOPMENT, ELIMINATES ONCOGENIC CELLS IN ADULTHOOD, AS WELL AS DAMAGED CELLS DURING AGING. WE IDENTIFIED ACTIVIN A AS AN IMPORTANT PLAYER DURING CELL COMPETITION, WHICH WE UNCOVERED TO BE A MAJOR ACTOR IN LIVER REPOPULATION BY TRANSPLANTED CELLS. WE SHOWED THAT ACTIVIN A IS PRODUCED BY HEPATOCYTES AND INCREASED IN AGING LIVER. HIGHLY PROLIFERATIVE FETAL LIVER STEM/PROGENITOR CELLS EXHIBIT REDUCED ACTIVIN RECEPTOR EXPRESSION, ARE RESISTANT TO ACTIVIN A, AND THEREFORE HAVE A GROWTH ADVANTAGE COMPARED TO MATURE HEPATOCYTES. AS A RESULT, TRANSPLANTED FETAL LIVER CELLS ARE CAPABLE TO REPOPULATE NORMAL LIVER. IN LIVERS WITH ADVANCED FIBROSIS, FETAL LIVER CELLS DIFFERENTIATE INTO FUNCTIONAL HEPATIC CELLS, EFFECTIVELY REPLACE INJURED LIVER, AND EXHIBIT ANTI-FIBROTIC EFFECTS. ALTHOUGH FETAL LIVER CELLS EXHIBIT THE CAPABILITY TO REPOPULATE THE LIVER, THEY WILL LIKELY NOT BE USED FOR HUMAN CELL TRANSPLANTATION. THUS, WE HYPOTHESIZE THAT MODULATING HEPATOCYTES OR INDUCED PLURIPOTENT STEM CELL-DERIVED TISSUES TO EXPRESS CRUCIAL FEATURES OF FETAL LIVER CELLS WILL GENERATE 'WINNERS' CAPABLE OF EFFECTIVELY RESTORING LIVER TISSUE MASS. GENERATING A CELL SOURCE WITH GROWTH-ADVANTAGE THAT IS ADAPTED TO AN INJURED MICROENVIRONMENT WILL ALLOW US TO ELUCIDATE THE MECHANISM OF CELL COMPETITION, WHICH CAN BE OF INVALUABLE THERAPEUTIC BENEFIT. HERE WE FIRST UNCOVER THE MECHANISM OF CELL COMPETITION IN LIVER, USING OUR RAT CELL TRANSPLANTATION MODEL AND MODULATED HEPATOCYTES. SECOND, WE WILL INVESTIGATE THE LIVER REPAIR EFFICACY OF COMPETING HUMAN HEPATOCYTES - INDUCED BY BLOCKING SPECIFICALLY ACTIVIN A-SIGNALING, USING A SMALL-MOLECULE-BASED HIGHLY SPECIFIC ACTIVIN A ANTAGONIST - IN DISEASED LIVER. FINALLY, WE WILL USE OUR RECENTLY DEVELOPED HUMAN FETAL LIVER ORGANOIDS FROM INDUCED PLURIPOTENT STEM CELLS TO PRODUCE LIVER PROGENITOR CELLS WITH COMPETITIVE ADVANTAGE TO REPOPULATE LIVER IN VIVO. OUR STUDIES WILL PAVE THE PATH TOWARDS NOVEL APPROACHES FOR THERAPEUTIC CELL TRANSPLANTATION IN LIVER AND APPLICATION FOR A DIVERSE SET OF LIVER DISEASES IN HUMAN POPULATION.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $683.3k | 5/23/25 | ||
| Not listed | $683.3k | 7/3/24 | ||
| Not listed | $683.3k | 7/3/24 |